

Appendix 4E

Final Report for the financial year ended 30 June 2025

Current Reporting Period: **30 June 2025**

Previous Reporting Period: **30 June 2024**

Results for Announcement to the Market

	12 months to 30 June 2025	12 months to 30 June 2024	% Change
	\$	\$	
Revenue from ordinary activities	-	-	0%
Loss from ordinary activities after tax attributable to members	(21,428,089)	(17,661,714)	21%
Net loss for the period attributable to members	(21,428,089)	(17,661,714)	21%

Brief Explanation of Results

Operational Report

During the reporting period, significant advances were made in support of the development of the Company's synthetic anti-infective programme. Some of the highlights for the year were as follows:

- Received approval from the Indonesian Drug and Food Regulatory Authority, Badan POM, to initiate Registrational Phase 3 clinical trial assessing RECCE® 327 Topical Gel (R327G) for the treatment of diabetic foot infections (DFIs).
- Received Human Research Ethics Committee (HREC) approval to commence a Registrational Phase 3 clinical trial of R327G for the treatment of DFIs in Indonesia.
- HREC approval to build upon Phase II Clinical Trial for the treatment of DFI by enrolling up to 20 additional patients to provide access to R327G in open-label study.
- Positive patient data analysis in its Phase II clinical trial of R327G for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). After 7-days of treatment, 86% of patients treated with R327G had a successful clinical response. At 14-days of treatment, 93% of patients achieved a primary efficacy endpoint.
- Independent non-Data Safety Monitoring Board (non-DSMB) completed review of safety and efficacy data from the Company's Phase II clinical trial of its lead compound, R327G, in patients with ABSSSI including DFIs.
- Successful dosing of all 30 patients in its Phase II clinical trial of R327G for the treatment of ABSSSI.

Appendix 4E

Final Report for the financial year ended 30 June 2025

- Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), with partnership and funding from the Defence Threat Reduction Agency.
- Grant funding in the amount of US\$2 million (approx. A\$3 million) by US Department of Defence in recognition of R327G as a topical treatment for Burn Wound Infections.
- Promising results from its study on the efficacy of R327 against multidrug resistant (MDR) World Health Organization (WHO) priority pathogen *Acinetobacter baumannii*.
- Successful A\$15.8 million capital raising consisting of A\$5.0 million private placement and 1-for-6 entitlement offer and shortfall placement to raise a further A\$10.8 million.
- Secured a debt facility of up to ~A\$30m (US\$20m) with ~A\$11.5m (US\$7.5m) committed and a further ~A\$19m (US\$12.5 million) available subject to draw down conditions from global investment firm Avenue Capital Group.
- International cash receipt of US\$175,122 (A\$271,987) from the Canadian Government as part of its Scientific Research & Experimental Development (SR&ED) Tax Incentive program.
- Raised A\$12.4 million through an institutional placement (\$A8.0 million) and Share Purchase Plan (A\$4.4 million).
- Received cash refund of AUD \$6,738,274 Research and Development (R&D) Tax Incentive rebate from the Australian Taxation Office for the financial year ending 30 June 2024.
- The Australian Patent Office formally granted Patent Family 3 for Recce's Anti-infectives, expiry 2037.
- Receipt of Notice of Acceptance from China National Intellectual Property Administration for Patent Family 4 for Recce's Anti-infective, expiry 2041.
- Receipt of notice of allowance from the Japan Patent Office for Patent Family 4 for Recce's Anti-infectives, expiry 2041.
- Delivered Opening Address and Opening R&D Address, as well as participated in a Panel Discussion focused on antimicrobial resistance at World AMR Congress 2024.
- The 2024 Annual Report for the financial year released.

Appendix 4E

Final Report for the financial year ended 30 June 2025

Financial Report

The operating loss has increased to \$21,428,089 (2024: loss of \$17,661,714) as a result of increased expenditure on research and development. The annual loss was after a R&D tax incentive of \$6,738,274 (2024: \$4,906,010).

The loss per share has increased during the year to 9.04 cents (2024: 9.97 cents).

The Group's focus is on progressing RECCE® 327 into human clinical trials.

	Amount per Security	Percentage Franked
Dividends		
Final Dividend	Nil	N/A
Interim Dividend	Nil	N/A
Date the Dividend is Payable:	N/A	N/A
Record Date for determining entitlements to the Dividends:	N/A	N/A

The Company did not declare a dividend during the financial year and has not declared a dividend since the end of the financial year.

Net Tangible Assets per Security

As at 30 June 2025 (cents)	(1.06)
As at 30 June 2024 (cents)	(4.67)

This announcement has been approved for release by the Recce Board.